采用三联疗法治疗放射性骨坏死的医学管理现状
Current trends in the medical management of osteoradionecrosis using triple therapy.
作者信息
Dhanda J, Rennie L, Shaw R
机构信息
Department of Maxillofacial Surgery, Queen Victoria Hospital, East Grinstead, UK.
Department of Molecular and Clinical Cancer Medicine, North West Cancer Research Centre, The University of Liverpool Cancer Research Centre, UK.
出版信息
Br J Oral Maxillofac Surg. 2018 Jun;56(5):401-405. doi: 10.1016/j.bjoms.2018.03.009. Epub 2018 Apr 9.
Recent guidelines from the National Institute for Health and Care Excellence (NICE) have suggested that the medical management of osteoradionecrosis (ORN) of the jaws should be used in clinical trials only, and some drugs and therapeutics committees have withdrawn funds for such prescriptions. With increased scrutiny on the use of these agents, the aims of this study were to ascertain current trends in the presentation and management of ORN, with particular focus on which agents are being used.
英国国家卫生与临床优化研究所（NICE）近期发布的指南建议，颌骨放射性骨坏死（ORN）的药物治疗仅应在临床试验中使用，一些药物和治疗委员会已停止为此类处方提供资金。随着对这些药物使用的审查日益严格，本研究的目的是确定ORN的当前表现和治疗趋势，尤其关注正在使用哪些药物。
Zotero 插件